Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression

  • Lena Seifert
  • , Gregor Werba
  • , Shaun Tiwari
  • , Nancy Ngoc Giao Ly
  • , Sara Alothman
  • , Dalia Alqunaibit
  • , Antonina Avanzi
  • , Rocky Barilla
  • , Donnele Daley
  • , Stephanie H. Greco
  • , Alejandro Torres-Hernandez
  • , Matthew Pergamo
  • , Atsuo Ochi
  • , Constantinos P. Zambirinis
  • , Mridul Pansari
  • , Mauricio Rendon
  • , Daniel Tippens
  • , Mautin Hundeyin
  • , Vishnu R. Mani
  • , Cristina Hajdu
  • Dannielle Engle, George Miller

Producción científica: Articlerevisión exhaustiva

541 Citas (Scopus)

Resumen

Neoplastic pancreatic epithelial cells are believed to die through caspase 8-dependent apoptotic cell death, and chemotherapy is thought to promote tumour apoptosis. Conversely, cancer cells often disrupt apoptosis to survive. Another type of programmed cell death is necroptosis (programmed necrosis), but its role in pancreatic ductal adenocarcinoma (PDA) is unclear. There are many potential inducers of necroptosis in PDA, including ligation of tumour necrosis factor receptor 1 (TNFR1), CD95, TNF-related apoptosis-inducing ligand (TRAIL) receptors, Toll-like receptors, reactive oxygen species, and chemotherapeutic drugs. Here we report that the principal components of the necrosome, receptor-interacting protein (RIP)1 and RIP3, are highly expressed in PDA and are further upregulated by the chemotherapy drug gemcitabine. Blockade of the necrosome in vitro promoted cancer cell proliferation and induced an aggressive oncogenic phenotype. By contrast, in vivo deletion of RIP3 or inhibition of RIP1 protected against oncogenic progression in mice and was associated with the development of a highly immunogenic myeloid and T cell infiltrate. The immune-suppressive tumour microenvironment associated with intact RIP1/RIP3 signalling depended in part on necroptosis-induced expression of the chemokine attractant CXCL1, and CXCL1 blockade protected against PDA. Moreover, cytoplasmic SAP130 (a subunit of the histone deacetylase complex) was expressed in PDA in a RIP1/RIP3-dependent manner, and Mincle-its cognate receptor-was upregulated in tumour-infiltrating myeloid cells. Ligation of Mincle by SAP130 promoted oncogenesis, whereas deletion of Mincle protected against oncogenesis and phenocopied the immunogenic reprogramming of the tumour microenvironment that was induced by RIP3 deletion. Cellular depletion suggested that whereas inhibitory macrophages promote tumorigenesis in PDA, they lose their immune-suppressive effects when RIP3 or Mincle is deleted. Accordingly, T cells, which are not protective against PDA progression in mice with intact RIP3 or Mincle signalling, are reprogrammed into indispensable mediators of anti-tumour immunity in the absence of RIP3 or Mincle. Our work describes parallel networks of necroptosis-induced CXCL1 and Mincle signalling that promote macrophage-induced adaptive immune suppression and thereby enable PDA progression.

Idioma originalEnglish
Páginas (desde-hasta)245-249
Número de páginas5
PublicaciónNature
Volumen532
N.º7598
DOI
EstadoPublished - abr 14 2016

Nota bibliográfica

Publisher Copyright:
© 2016 Macmillan Publishers Limited. All rights reserved.

Financiación

This work was supported by grants from the German Research Foundation (L.S.), the National Pancreas Foundation (C.P.Z.), the Pancreatic Cancer Action Network (G.M.), the Lustgarten Foundation (G.M.), and National Institute of Health Awards CA155649 (G.M.), CA168611 (G.M.), and CA193111 (G.M., A.T.-H.). We thank the New York University Langone Medical Center (NYU LMC) Histopathology Core Facility, the NYU LMC Flow Cytometry Core Facility, the NYU LMC Microscopy Core Facility, and the NYU LMC BioRepository Center, each supported in part by the Cancer Center Support Grant P30CA016087 and by grant UL1 TR000038 from the National Center for the Advancement of Translational Science (NCATS).

FinanciadoresNúmero del financiador
Markey Cancer Center's Cancer Center SupportP30CA016087, UL1 TR000038
National Center for the Advancement of Translational Science
National Institutes of Health (NIH)CA168611, CA155649
National Institutes of Health (NIH)
National Childhood Cancer Registry – National Cancer InstituteT32CA193111
National Childhood Cancer Registry – National Cancer Institute
Pancreatic Cancer Action Network
National Pancreas Foundation
Lustgarten Foundation
NYU Langone Medical Center, Division of Cardiology
Deutsche Forschungsgemeinschaft

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • General

    Huella

    Profundice en los temas de investigación de 'The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression'. En conjunto forman una huella única.

    Citar esto